Nvidia collaboration

Channel Insider content and product recommendations are editorially independent. We may make money when you click on links to our partners. View our editorial policy here.

Multinational tech giant NVIDIA made a handful of recent announcements that highlight its participation in the AI revolution permeating the healthcare industry. 

During a press briefing, Kimberly Powell, Vice President of Healthcare at NVIDIA, broke down NVIDIA’s recent moves in the AI and healthcare space, including collaborating with other entities to enable new products and services with AI.

NVIDIA is fostering partnerships with several organizations as the convergence of AI, accelerated computing, and biological data turns healthcare into the largest technology industry. These partnerships include collaborations with IQVIA for clinical trials, Illumina for genomics insights, the Mayo Clinic for pathology models, and the Arc Institute for biology AI models.

Currently, NVIDIA’s AI enterprise platform supports over 1,000 healthcare startups developing AI agents. 

NVIDIA’s newest collaborations

IQVIA partnership to boost drug and medical device deployment

Among the announcements include clinical research leader IQVIA partnering with NVIDIA in their AI foundry and factory platforms and services to accelerate their development and deployment of AI agents for their over 10,000 customers across healthcare and life sciences.

“IQVIA and the NVIDIA AI Foundry is going to really help IQVIA streamline custom model development using NVIDIA NIMs, our newly announced Llama Nemotron models, our AI blueprints as reference workflows, and the NEMO platform on dedicated capacity of NVIDIA DGX cloud,” said Powell. “NVIDIA’s collection of models, AI agents, and reference workflows will be made available through their IQVIA healthcare-grade AI solutions to its global pharmaceutical, biotech, and med device customers.”

Powell says that the partnership is going to focus initially on clinical trials. The partnership will accelerate trial execution while significantly reducing the administrative burden through the deployment of agents of all kinds. 

NVIDIA will also be releasing its latest generation of molecular generation NIM called GenMol, a goal-directed molecular generation NIM that is going to be utilized for virtual screening. 

Arc Institute collaboration to scale biology AI models

Arc Institute, a California-based research organization, will be collaborating with NVIDIA to develop and share powerful AI models and tools to enhance biomedical discovery. 

“If we want to scale science, we must use machine learning, and if we need machine learning for science, we need the AI factories to do it,” Powell said. “Arc is pioneering a new model in scientific acceleration. They have very non-traditional funding approaches, they have long-term thinking, and they are all about cutting-edge technology centers, which we’re partnering with them on and building at their computational technology center.”

As part of this collaboration, NVIDIA is providing Arc Institute with expertise in large-scale model development, the NVIDIA BioNeMo platform running on NVIDIA DGX Cloud for easy-to-use, optimized training, and NVIDIA NIM microservices and blueprints.

Mayo Clinic collaboration to develop NextGen pathology foundation models

NVIDIA will also collaborate with Mayo Clinic to accelerate the development of next-generation pathology foundation models to push the frontiers in personalized health experiences, as well as predictive and efficient treatment strategies. 

“Mayo Clinic will deploy NVIDIA DGX Blackwell, featuring 1.4 terabytes of GPU memory. This is ideal for handling those large digital pathology whole slide images and these systems will integrate with NVIDIA’s MONAI,” said Powell.

Powell also states that the company’s ultimate goal is to create a human digital twin, a dynamic digital representation that includes medical imaging, pathology, health records, and wearables. To achieve this, Mayo Clinic and NVIDIA will leverage the latest AI models and vision language models like NVIDIA Cosmos Nemotron and NIM microservices.

Illumina partnership to boost genomic breakthroughs

Lastly, NVIDIA will be working with Ilumina, a global leader in DNA sequencing and informatics technologies, to unlock next-generation genomics for drug discovery and human health. 

Through this partnership, Illumina will be enabled to use NVIDIA accelerated computing and AI toolsets for multiomics analysis software and workflows. Illumina will offer DRAGEN analysis software on NVIDIA accelerated computing within the Illumina Connected Analytics platform. The integration will expand DRAGEN accessibility globally to wherever NVIDIA’s computing platform exists. 

“This collaboration will combine Illumina’s world-leading sequencing technologies and their connected analytics platform with all of NVIDIA’s Clara AI tools to develop and deploy foundation models that unlock the next generation of genomics insights, truly expanding the opportunities of genomics into more areas of drug discovery and precision health,” said Powell. “Our partnership will revolutionize the analysis and interpretation of multiomics data.”

NVIDIA’s AI enterprise and healthcare startups

NVIDIA has over 1,000 digital healthcare startups in their program developing thousands of AI agents. These agents are built with NVIDIA AI enterprise, which provides them all with the essential building blocks for AI creators from pre-trained models to state-of-the-art retrieval, augmented, generation, and guardrails for agentic AI.

“These AI agents are like knowledge robots,” Powell said. “They’re designed to assist healthcare staff or enhance patient experiences and improve operations. For example, Abridge uses AI agents to automate clinical documentation in real-time, converting these patient clinic and clinician conversations into structured clinical notes. This is saving doctors up to three hours of clerical work every single day.”

Among other AI agents partnered with NVIDIA, include Intrivo’s AI agent called Ray, a natural and emotionally intelligent tool that acts as a medical concierge that meets user needs while helping navigate healthcare solutions, and Hippocratic AI which made some recent announcements concerning their agents, including how their agents are helping healthcare providers during natural disasters. 

Evolution of AI and its applications in healthcare

NVIDIA sees AI agents as digital employees and they’re becoming the new enterprise applications. The next phase of AI is poised to be physical AI, which includes having physical robots and a physical environment all operating and embodying AI in the physical world. 

“Every single nation is struggling to meet the demands of aging populations and chronic disease management,” said Powell. “AI agents, AI instruments, and AI robots will be powered by AI factories, running large language models, running biology foundation models, running world foundation models, and assembling these models into agents that perform tasks.”

AI of all kinds is going to be required to meet the growing demand of healthcare and 2025 will be a critical year along this journey. 

Conclusion and vision for AI in healthcare

The healthcare industry is a $10 trillion industry, with over 30 percent of operating expenses being dedicated to meeting the growing demand. 

“No single company can achieve this alone,” said Powell. “The incredible ecosystem and partnerships we’ve just announced will demonstrate this rapid adoption of NVIDIA AI by the world’s leading companies in the industry. We’re on a mission to improve patient care, increase the accessibility, and, together, we’re going to write the next chapter in medicine.”

NVIDIA AI tools aim to transform healthcare, from drug discovery to physical AI in hospitals, and to develop solutions that help advance human health.

NVIDIA continues to make moves in the AI space both inside and outside of the healthcare space. Read more about NVIDIA’s recent AI collaboration with Accenture and KION on AI-powered digital twins.

Subscribe for updates!

You must input a valid work email address.
You must agree to our terms.